ESR2
Summary: This gene encodes a member of the family of estrogen receptors and superfamily of nuclear receptor transcription factors. The gene product contains an N-terminal DNA binding domain and C-terminal ligand binding domain and is localized to the nucleus, cytoplasm, and mitochondria. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription. Some isoforms dominantly inhibit the activity of other estrogen receptor family members. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been fully characterized. [provided by RefSeq, Jul 2008].
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
estrogen receptor 2 | MIM:601663 | Ensembl:ENSG00000140009 | HGNC:HGNC:3468 | PA27886 | 14q23.2-q23.3 |
GO terms in ESR2
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
MF | IDA | GO:0000978 | RNA polymerase II proximal promoter sequence-specific DNA binding |
MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | NAS | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | TAS | GO:0003677 | DNA binding |
MF | TAS | GO:0003700 | DNA-binding transcription factor activity |
MF | TAS | GO:0003707 | steroid hormone receptor activity |
MF | TAS | GO:0003713 | transcription coactivator activity |
MF | NAS | GO:0004879 | nuclear receptor activity |
MF | ISS | GO:0005496 | steroid binding |
MF | TAS | GO:0005496 | steroid binding |
MF | IPI | GO:0005515 | protein binding |
MF | IEA | GO:0008270 | zinc ion binding |
MF | IPI | GO:0019899 | enzyme binding |
MF | TAS | GO:0030284 | estrogen receptor activity |
MF | IDA | GO:0034056 | estrogen response element binding |
MF | IDA | GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding |
MF | IPI | GO:0042802 | identical protein binding |
MF | NAS | GO:0048019 | receptor antagonist activity |
CC | IEA | GO:0005576 | extracellular region |
CC | IDA | GO:0005634 | nucleus |
CC | TAS | GO:0005634 | nucleus |
CC | TAS | GO:0005654 | nucleoplasm |
CC | IDA | GO:0005739 | mitochondrion |
BP | IDA | GO:0000122 | negative regulation of transcription by RNA polymerase II |
BP | TAS | GO:0006355 | regulation of transcription, DNA-templated |
BP | TAS | GO:0006367 | transcription initiation from RNA polymerase II promoter |
BP | TAS | GO:0007165 | signal transduction |
BP | TAS | GO:0007267 | cell-cell signaling |
BP | NAS | GO:0030308 | negative regulation of cell growth |
BP | TAS | GO:0030520 | intracellular estrogen receptor signaling pathway |
BP | IDA | GO:0045893 | positive regulation of transcription, DNA-templated |
BP | IDA | GO:0051091 | positive regulation of DNA-binding transcription factor activity |
BP | IEA | GO:1900116 | extracellular negative regulation of signal transduction |
Gene expression in normal tissue: ESR2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in ESR2
Database | Pathway ID | Pathway Des. |
---|---|---|
pharmgkb | PA145011120 | Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics |
pid | er_nongenomic_pathway | Plasma membrane estrogen receptor signaling |
pid | era_genomic_pathway | Validated nuclear estrogen receptor alpha network |
pid | erb_genomic_pathway | Validated nuclear estrogen receptor beta network |
kegg | hsa04915 | Estrogen signaling pathway - Homo sapiens (human) |
kegg | hsa04917 | Prolactin signaling pathway - Homo sapiens (human) |
kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
kegg | hsa05224 | Breast cancer - Homo sapiens (human) |
wikipathways | WP170 | Nuclear Receptors |
wikipathways | WP34 | Ovarian Infertility Genes |
wikipathways | WP706 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways |
reactome | R-HSA-1257604 | PIP3 activates AKT signaling |
reactome | R-HSA-162582 | Signal Transduction |
reactome | R-HSA-1643685 | Disease |
reactome | R-HSA-199418 | Negative regulation of the PI3K/AKT network |
reactome | R-HSA-212436 | Generic Transcription Pathway |
reactome | R-HSA-2219528 | PI3K/AKT Signaling in Cancer |
reactome | R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer |
reactome | R-HSA-383280 | Nuclear Receptor transcription pathway |
reactome | R-HSA-5663202 | Diseases of signal transduction |
reactome | R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling |
reactome | R-HSA-73857 | RNA Polymerase II Transcription |
reactome | R-HSA-74160 | Gene expression (Transcription) |
reactome | R-HSA-8939211 | ESR-mediated signaling |
reactome | R-HSA-9006925 | Intracellular signaling by second messengers |
reactome | R-HSA-9006931 | Signaling by Nuclear Receptors |
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD309 | 17AAG | 1 |
iGMDRD870 | BRD63610 | 3 |
iGMDRD52 | Rotenone | 3 |
iGMDRD441 | TW 37 | 1 |
iGMDRD782 | DC-45-A2 | 6 |
iGMDRD6 | AM-580 | 3 |
iGMDRD271 | Brefeldin A | 3 |
iGMDRD524 | ISX-9 | 3 |
iGMDRD322 | FK 866 | 3 |
iGMDRD23 | Gossypol | 5 |
iGMDRD82 | Quiflapon | 3 |
iGMDRD300 | Tozasertib | 1 |
iGMDRD562 | Navitoclax | 3 |
iGMDRD398 | Sepantronium | 2 |
iGMDRD888 | Compound 44 | 3 |
iGMDRD577 | BIX01294 | 4 |
iGMDRD871 | BRD6368 | 3 |
iGMDRD367 | Ro 28-1675 | 3 |
iGMDRD494 | Neopeltolide | 3 |
iGMDRD427 | ABT737 | 9 |
iGMDRD560 | MK-2206 | 1 |
iGMDRD420 | Leucascandrolide A | 2 |
iGMDRD248 | BRD4354 | 3 |
iGMDRD579 | PF750 | 3 |
iGMDRD599 | Salermide | 6 |
iGMDRD889 | Compound 7d-cis | 3 |
iGMDRD330 | BRD4132 | 3 |
iGMDRD375 | GW-405833 | 3 |
iGMDRD351 | GW843682X | 6 |
iGMDRD718 | Pyrvinium pamoate | 3 |
iGMDRD71 | Sparfosic acid | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in ESR2